Similar articles

• [Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine].

  Moerkens RM, Dhondt AD. Moerkens RM, et al. Ned Tijdschr Geneeskd. 2003 Apr 5;147(14):679; author reply 679. Ned Tijdschr Geneeskd. 2003. PMID: 12712654 Dutch. No abstract available.
• [Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine].

  Mol JA. Mol JA. Ned Tijdschr Geneeskd. 2003 Apr 5;147(14):679; author reply 679. Ned Tijdschr Geneeskd. 2003. PMID: 12712655 Dutch. No abstract available.
• Understanding changes in cholinergic function: implications for treating dementia.

  [No authors listed] [No authors listed] J Clin Psychiatry. 2002 Mar;63(3):259-69. doi: 10.4088/jcp.v63n0316. J Clin Psychiatry. 2002. PMID: 11926730 Review. No abstract available.
• Rivastigmine for Alzheimer's disease.

  [No authors listed] [No authors listed] Drug Ther Bull. 2000 Feb;38(2):15-6. Drug Ther Bull. 2000. PMID: 10829350 Review.
• Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.

  Linkins KW, Lloyd JR, Hjelmstad GO, Strausbaugh HJ. Linkins KW, et al. Pharmacoeconomics. 2000 Dec;18(6):609-12. doi: 10.2165/00019053-200018060-00007. Pharmacoeconomics. 2000. PMID: 11227398 No abstract available.